Merck & Co., Inc. (NYSE:MRK) Trading Down 1.9% - Should You Sell?

Key Points

• Merck shares fell 1.9% to about $144.68 in mid-day trading, while volume was 31% below the average session level.
• Analyst sentiment remains broadly positive: HSBC, Guggenheim, Leerink Partners and others raised price targets, with 17 analysts rating the stock a Buy and eight a Hold. The consensus rating is “Moderate Buy,” with an average target of $151.32.
• Keytruda’s approaching patent expiration remains the main risk, though Merck is pursuing antibody-drug conjugate combinations and other oncology opportunities to replace potential lost revenue. The company also reported quarterly revenue above expectations and declared a $0.85 quarterly dividend.

Shares of Merck & Co., Inc. (NYSE:MRK - Get Free Report) traded down 1.9% during mid-day trading on Thursday . The company traded as low as $144.10 and last traded at $144.6840. Approximately 7,442,642 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 10,754,442 shares. The stock had previously closed at $147.53.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increases signal confidence. HSBC raised its target from $150 to $172 and assigned a “buy” rating, while Guggenheim lifted its target to $170. Leerink Partners also increased its target from $127 to $161 and upgraded its view to “outperform.” These revisions suggest analysts see additional value in MRK’s pipeline and business outlook. Guggenheim increases Merck price target
• Positive Sentiment: Merck is pursuing new oncology growth opportunities. The company is pairing antibody-drug conjugates (ADCs) with Keytruda in women’s cancers, a strategy intended to improve treatment options and build replacement revenue as Keytruda approaches patent expiration. Merck pairs ADCs with Keytruda
• Neutral Sentiment: Investor attention remains elevated. Zacks highlighted MRK as one of the stocks attracting significant user interest, but the report does not identify a new fundamental catalyst. Merck’s recent Wells Fargo healthcare-conference presentation may provide additional insight into pipeline progress and strategy. Zacks Merck investor attention report
• Negative Sentiment: Keytruda concentration remains the central risk. Although the ADC strategy is a potential long-term offset, investors may remain cautious about how quickly Merck can replace revenue and earnings threatened by the blockbuster drug’s patent expiration. That concern may be weighing on the stock despite bullish analyst targets.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MRK. Guggenheim increased their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday. Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an "outperform" rating to a "sector perform" rating and increased their price target for the stock from $142.00 to $150.00 in a report on Thursday, August 20th. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Wells Fargo & Company lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Finally, Argus upped their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday, August 25th. Seventeen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $151.32.

Merck & Co., Inc. Trading Down 1.9%

The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a 50-day simple moving average of $135.91 and a 200 day simple moving average of $124.10. The firm has a market cap of $356.96 billion, a PE ratio of 115.75, a price-to-earnings-growth ratio of 6.46 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business's quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 in the last ninety days. 0.17% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. High Note Wealth LLC increased its stake in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.